**
In the wake of a devastating Ebola outbreak in the Democratic Republic of the Congo (DRC), health authorities have rapidly initiated a groundbreaking treatment trial, enrolling its first patients just weeks after the World Health Organization (WHO) declared the crisis a public health emergency. This proactive approach aims to test two experimental drugs, offering hope to a region grappling with significant mortality rates associated with the Bundibugyo strain of the virus.
Swift Action in the Face of Crisis
On 17 May, the WHO classified the ongoing Ebola outbreak as a global health emergency, prompting an urgent response from medical professionals and researchers. By early July, health workers in the Ituri region had commenced a clinical trial, a remarkable feat accomplished within just six weeks of the emergency declaration. This rapid mobilisation underscores the critical need for effective treatment options, as the DRC faces a dire situation with 1,792 confirmed cases and 625 deaths reported by 9 July.
Neema Haba, a local mother and banana vendor, expressed the frustrations of many in the community: “I hope these drug trials proceed quickly. Financially, we are being driven to the brink by this outbreak, and nothing is going right. We are struggling to provide for our children.” The urgency of the situation is palpable as families contend with the dual threats of the virus and economic instability.
The Challenge of Containment
The ongoing outbreak is characterised by a lack of approved treatments or vaccines, compelling health officials to rely on traditional methods of case identification, isolation, and contact tracing. Despite efforts, only about 75% of known contacts are being traced, hindered by a lack of trust in authorities and the region’s mobile population. Protest actions by frontline workers over unpaid wages have further complicated the response, creating an environment of fear and frustration among those risking their lives to combat the virus.
Ovide Maliabo, a driver for a burial team, described the perilous nature of their work amidst community scepticism. “At one point, we narrowly escaped being lynched. It’s a shame that we aren’t being financially supported.” His sentiments reflect the broader discontent among health workers, who report severe shortages of essential equipment, including personal protective gear and transportation for deceased victims.
Promising Potential of Experimental Treatments
The newly launched Partners treatment trial is set to evaluate the efficacy of two drugs: remdesivir, an antiviral agent developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. Patients will be randomly assigned to receive either drug, a combination of the two, or standard supportive care. Both treatments have demonstrated significant effectiveness against the Bundibugyo strain in animal studies, but their performance in humans remains to be seen.
Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp emphasised the importance of these trials: “We want to see if they can indeed lower mortality.” While the Bundibugyo strain typically has a lower mortality rate compared to the more lethal Zaire strain, it still results in the death of approximately one in three infected individuals.
The trial is designed to accommodate up to 1,200 patients, including vulnerable populations such as pregnant and breastfeeding women, who are often excluded from medical research. This inclusivity reflects a crucial shift towards ensuring that the most at-risk groups receive potentially life-saving interventions.
Global Collaboration and Future Prospects
The Partners trial has garnered support from the WHO, with funding from various international organisations, including the Wellcome Trust and the UK’s Foreign, Commonwealth & Development Office. Prof Amanda Rojek, an international principal investigator from the University of Oxford, praised the swift initiation of the trial, noting the leadership and experience of the DRC’s National Biomedical Research Institute in managing previous health crises.
As researchers prepare to monitor patient outcomes closely, the trial’s design allows for the potential inclusion of further treatments if they become available. “These trials will enable us to access treatment, and when we treat people, it also sends a message to the community,” remarked Prof Yap Boum from the Africa CDC.
A separate trial is also set to commence, aimed at evaluating whether obeldesivir can prevent Ebola in individuals exposed to the virus. The Africa CDC requires approximately $18 million to fund this initiative, with $6 million already pledged.
Why it Matters
The outbreak of Ebola in the DRC represents not only a public health crisis but also a test of the global community’s commitment to swift, effective intervention in the face of infectious diseases. The success of these treatment trials could significantly alter the trajectory of this outbreak and provide crucial insights for managing future health emergencies. By prioritising rapid research and inclusive patient access, the DRC is setting a precedent for how nations can respond to outbreaks with urgency and compassion, ultimately saving lives in vulnerable communities.
